UA106710C2 - COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT - Google Patents

COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT

Info

Publication number
UA106710C2
UA106710C2 UAA201312949A UAA201312949A UA106710C2 UA 106710 C2 UA106710 C2 UA 106710C2 UA A201312949 A UAA201312949 A UA A201312949A UA A201312949 A UAA201312949 A UA A201312949A UA 106710 C2 UA106710 C2 UA 106710C2
Authority
UA
Ukraine
Prior art keywords
compounds
salts
mutant
substituted anilino
pirimidine
Prior art date
Application number
UAA201312949A
Other languages
Ukrainian (uk)
Inventor
Сем Баттерворс
Мауріс Реймонд Вершоіл Фінлі
Річард Ендрю Ворд
Васанта Крішна Кадамбар
Чандрасекхара Редді Чінтакунтла
Андіппан Муруґан
Хізер Мері Редфеарн
Клаудіо Едмундо Чуакуй
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Priority claimed from PCT/GB2012/051783 external-priority patent/WO2013014448A1/en
Publication of UA106710C2 publication Critical patent/UA106710C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Abstract

Заявлений винахід стосується певних сполук 2-(2,4,5-заміщений аніліно)піримідину та її фармацевтично прийнятних солей, які можуть бути корисними в лікуванні або попередженні хвороби або медичного стану, опосередкованого через певні мутантні форми рецептора фактора росту епідермісу (наприклад, як-то активувальний мутант L858R, мутант делеції Ехоn19 та резистентнтний мутант Т790М).Такі сполуки та їх солі можуть бути корисними в лікуванні або попередженні кількості різних видів раку.Винахід також стосується фармацевтичних композицій, які містять названі сполуки та їх солі, зокрема придатні поліморфні форми цих сполук та солей, проміжних сполук, придатних для виготовлення названих сполук, та способів лікування хвороб, опосередкованих різними відмінними формами EGFR, застосовуючи названі сполуки та їх солі.The present invention relates to certain compounds 2- (2,4,5-substituted anilino) pyrimidine and its pharmaceutically acceptable salts, which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutant forms of the epidermal growth factor receptor (eg, as is an activating mutant L858R, a deletion mutant Echon19 and a resistant mutant T790M). Such compounds and their salts may be useful in the treatment or prevention of various cancers. The invention also relates to pharmaceutical compositions containing said compounds and their salts, in particular suitable polymorphic forms of these compounds and salts, intermediates suitable for the manufacture of said compounds, and methods of treating diseases mediated by various different forms of EGFR using said compounds and their salts.

UAA201312949A 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT UA106710C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512061P 2011-07-27 2011-07-27
PCT/GB2012/051783 WO2013014448A1 (en) 2011-07-27 2012-07-25 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer

Publications (1)

Publication Number Publication Date
UA106710C2 true UA106710C2 (en) 2014-09-25

Family

ID=53675818

Family Applications (3)

Application Number Title Priority Date Filing Date
UAA201403622A UA109736C2 (en) 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)
UAA201312949A UA106710C2 (en) 2011-07-27 2012-07-25 COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
UAA201403623A UA108954C2 (en) 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201403622A UA109736C2 (en) 2011-07-27 2012-07-25 POLYMORPH FORM OF MESILATE SALT 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE (OPTIONS)

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201403623A UA108954C2 (en) 2011-07-27 2012-07-25 Compounds 2- (2,4,5-substituted aniline) pyrimidine

Country Status (2)

Country Link
AR (1) AR115019A2 (en)
UA (3) UA109736C2 (en)

Also Published As

Publication number Publication date
UA108954C2 (en) 2015-06-25
UA109736C2 (en) 2015-09-25
AR115019A2 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
PH12015501326A1 (en) 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
EA201590624A1 (en) CYCLIC ETHERS OF PYRAZOL-4-IL-HETEROCYCLIL-CARBOXAMIDE COMPOUNDS AND METHODS OF THEIR APPLICATION
MX2012013206A (en) Fused bicyclic kinase inhibitors.
MX2016004030A (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease.
EA201590345A1 (en) METHODS OF CANCER TREATMENT USING 3- (4 - ((4- (MORFOLINOMETHYL) BENZYL) OXY) -1-OXIOIZINDOLIN-2-IL) PIPERIDIN-2,6-DIONA
EA201291220A1 (en) AMINOPYRIMIDINE DERIVATIVES AS MODULATORS LRRK2
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
EA201370166A1 (en) CONTAINING DIRYLACETHYLENEHYDRAZIDE THYROZINKINASE INHIBITORS
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
EA201300250A1 (en) OXADIAZOL INHIBITORS OF LEUKOTRIEN PRODUCTION
MX2013008431A (en) Mineralocorticoid receptor antagonists.
EA201790246A1 (en) HETEROCYCLIC CARBONIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATZYCLIC
MX2012002761A (en) Bipyridines useful for the treatment of proliferative diseases.
EA201990678A1 (en) Heteroarylcarboxamide Compounds as Ripk2 Inhibitors
EA201692260A1 (en) 1,3,4-TIADIAZOLE COMPOUNDS AND THEIR APPLICATION IN CANCER TREATMENT
PH12020550228A1 (en) Epidermal growth factor receptor inhibitors
ATE540038T1 (en) HETEROCYCLES AS PROTEIN KINASE INHIBITORS
EA201390771A1 (en) METHOD OF OBTAINING PHARMACEUTICAL INTERMEDIATE COMPOUNDS OF HIGH PURITY
IN2013DN02555A (en)
UA106710C2 (en) COMPOUND 2- (2,4,5-substituted ANILINO) PIRIMIDINE AND ITS APPLICATION FOR CANCER TREATMENT
EA202092034A3 (en) 2- (2,4,5-SUBSTITUTED ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR CANCER TREATMENT
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TH149236B (en) 2- (2,4,5- replaces -anilino) pyrimidine derivatives, an EGFR regulator, are useful in the treatment of cancer.